Wingless-type MMTV integration site family (WNT)16 is a key regulator of bone mass with high expression in cortical bone, and Wnt16 −/− mice have reduced cortical bone mass. As Wnt16 expression is enhanced by estradiol treatment, we hypothesized that the bone-sparing effect of estrogen in females is WNT16-dependent. This hypothesis was tested in mechanistic studies using two genetically modified mouse models with either constantly high osteoblastic Wnt16 expression or no Wnt16 expression. We developed a mouse model with osteoblast-specific Wnt16 overexpression (Obl-Wnt16). These mice had several-fold elevated Wnt16 expression in both trabecular and cortical bone compared with wild type (WT) mice. OblWnt16 mice displayed increased total body bone mineral density (BMD), surprisingly caused mainly by a substantial increase in trabecular bone mass, resulting in improved bone strength of vertebrae L 3 . Ovariectomy (ovx) reduced the total body BMD and the trabecular bone mass to the same degree in Obl-Wnt16 mice and WT mice, suggesting that the bone-sparing effect of estrogen is WNT16-independent. However, these bone parameters were similar in ovx OblWnt16 mice and sham operated WT mice. The role of WNT16 for the bone-sparing effect of estrogen was also evaluated in Wnt16 −/− mice. Treatment with estradiol increased the trabecular and cortical bone mass to a similar extent in both Wnt16 −/− and WT mice. In conclusion, the bone-sparing effects of estrogen and WNT16 are independent of each other. Furthermore, loss of endogenous WNT16 results specifically in cortical bone loss, whereas overexpression of WNT16 surprisingly increases mainly trabecular bone mass. WNT16-targeted therapies might be useful for treatment of postmenopausal trabecular bone loss.
Wingless-type MMTV integration site family (WNT)16 is a key regulator of bone mass with high expression in cortical bone, and Wnt16 −/− mice have reduced cortical bone mass. As Wnt16 expression is enhanced by estradiol treatment, we hypothesized that the bone-sparing effect of estrogen in females is WNT16-dependent. This hypothesis was tested in mechanistic studies using two genetically modified mouse models with either constantly high osteoblastic Wnt16 expression or no Wnt16 expression. We developed a mouse model with osteoblast-specific Wnt16 overexpression (Obl-Wnt16). These mice had several-fold elevated Wnt16 expression in both trabecular and cortical bone compared with wild type (WT) mice. OblWnt16 mice displayed increased total body bone mineral density (BMD), surprisingly caused mainly by a substantial increase in trabecular bone mass, resulting in improved bone strength of vertebrae L 3 . Ovariectomy (ovx) reduced the total body BMD and the trabecular bone mass to the same degree in Obl-Wnt16 mice and WT mice, suggesting that the bone-sparing effect of estrogen is WNT16-independent. However, these bone parameters were similar in ovx OblWnt16 mice and sham operated WT mice. The role of WNT16 for the bone-sparing effect of estrogen was also evaluated in Wnt16 −/− mice. Treatment with estradiol increased the trabecular and cortical bone mass to a similar extent in both Wnt16 −/− and WT mice. In conclusion, the bone-sparing effects of estrogen and WNT16 are independent of each other. Furthermore, loss of endogenous WNT16 results specifically in cortical bone loss, whereas overexpression of WNT16 surprisingly increases mainly trabecular bone mass. WNT16-targeted therapies might be useful for treatment of postmenopausal trabecular bone loss.
WNT16 | estrogen | cortical bone | trabecular bone | transgenic mice B oth estrogen and wingless-type MMTV integration site family (WNT)16 are crucial regulators of bone mass in women (1) (2) (3) (4) (5) . The bone-sparing effect of estrogen is primarily mediated via estrogen receptor-α (ERα) (6) . Estrogen-deficiency leads to rapid bone loss and contributes significantly to the development of postmenopausal osteoporosis that can be prevented by estradiol treatment. However, this treatment is associated with side effects such as breast cancer and thromboembolism (7, 8) .
The WNTs are a family of secreted glycoproteins that consists of 19 members in mammals, and which mediates autocrine and paracrine effects by binding to frizzled (Fzd) receptors and LDL-related protein 5/6 (LRP5/6) coreceptors (9) . During the last decade, several lines of clinical and preclinical evidence have indicated that WNT signaling is critical in bone development and in the regulation of adult bone homeostasis (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) and modulation of WNT signaling has emerged as a promising strategy for increasing bone mass (21) (22) (23) . Crosstalk and synergy between ERα signaling and the WNT pathways have been described (24) (25) (26) . In the brain, estrogen signaling activates WNT by down-regulating dickkopf-1 (Dkk1), a WNT antagonist, to prevent neurodegeneration (27) . In the uterus, estrogen prompts the canonical WNT signaling pathway in the uterine epithelium to induce uterine epithelial cell growth (28) , and in breast cancer, ERα activation enhances cell growth via WNT signaling (29) .
Human genetic studies followed by subsequent mechanistic studies have recently revealed that WNT16 is a key physiological regulator of cortical bone mass and nonvertebral fracture risk (4, 5, (30) (31) (32) (33) . We recently demonstrated that WNT16 is osteoblast-derived and inhibits osteoclastogenesis both directly by acting on osteoclast progenitors and indirectly by increasing expression of osteoprotegerin (Opg) in osteoblasts (3). WNT16 is highly expressed in cortical bone but, for unknown reasons, only moderately expressed in trabecular bone. Experiments using WNT16-deleted mouse models clearly show that absence of WNT16 results in reduced cortical but not trabecular bone mass (3, 4, 30, 34) . However, the effects of pharmacologically increased WNT16 levels on the cortical and trabecular bone compartments are unexplored. Furthermore, the role of WNT16 for the bonesparing effect of estrogen is unknown. Herein we first demonstrate that the expression of WNT16 is enhanced by estradiol treatment, and we therefore hypothesized that the bone-sparing Significance Previous studies demonstrate that endogenous wingless-type MMTV integration site family (WNT)16 is a crucial regulator of cortical bone mass. Surprisingly, we demonstrate that overexpression of WNT16 increases mainly trabecular bone mass. Both estrogen and WNT16 are crucial regulators of bone mass, but the possible interaction between WNT16-signaling and estrogen-signaling is unknown. To determine the possible interaction between WNT16 and estrogen signaling in bone, we developed and used two genetically modified mouse models with either constantly high osteoblastic Wnt16 expression or no Wnt16 expression. We demonstrated that the bone-sparing effects of estrogen and WNT16 are independent of each other. As WNT16 signaling in bone does not require normal estrogen action, we propose that WNT16-targeted therapies might be useful for treatment of postmenopausal trabecular bone loss.
effects of estrogen are WNT16-mediated. This hypothesis was tested in mechanistic studies using two different genetically modified mouse models in which estrogen does not have the capacity to regulate WNT16 levels. Contradicting our hypothesis, we demonstrate that the bone-sparing effects of estrogen and WNT16 are independent of each other. In addition, unexpectedly, we demonstrate that overexpression of WNT16 increases mainly trabecular bone mass. 
Obl-

Results
Overexpression of Wnt16 in Osteoblasts Substantially Increases
Trabecular Bone Mass. We initially observed that Wnt16 expression in bone is enhanced by estradiol treatment in ovx female mice ( Fig. 1A ) and, therefore, we hypothesized that the bonesparing effects of estrogen are WNT16-dependent. We first aimed to test this hypothesis in a mouse model with constant high Wnt16 levels in bone. To this end we developed a transgenic mouse model (Obl-Wnt16) with osteoblast-specific Wnt16 overexpression under the control of a 2.3-kb fragment of the rat type I α 1 procollagen promoter ( Fig. 1 B-K and Tables S1-S4 ). The Obl-Wnt16 mice displayed a specific and high overexpression of Wnt16 in bone (Fig.  1C) . The endogenous moderate Wnt16 expression in trabecular bone was elevated 140-fold (P < 0.01), whereas the endogenous high Wnt16 expression in cortical bone was increased 9-fold (P < 0.01) in Obl-Wnt16 mice compared with WT mice, but still the Wnt16 expression was higher in cortical bone than in trabecular bone in Obl-Wnt16 mice (Fig. 1C) . There was no change in Wnt16 expression in the uterus in the Obl-Wnt16 mice compared with WT mice (P = 0.3). The Obl-Wnt16 mice were born at a normal Mendelian distribution, were apparently healthy and had unaffected tibia length, body weight and weights of several visceral organs compared with WT mice ( Fig. 2A and Table S1 ). DXA analysis revealed that the Obl-Wnt16 mice had increased total body and lumbar spine (LS) BMD compared with WT mice both before (5-wk-old) and after (11-and 16-wk-old) sexual maturation (P < 0.05; Figs. 1 D and E and 2B). The trabecular and cortical bone compartments were analyzed separately at 16 wk of age using high-resolution μCT and histomorphometry. The trabecular bone volume fraction (BV/TV) was substantially increased (+106%, P < 0.01) in the distal metaphyseal region of femur in Obl-Wnt16 mice compared with WT mice and this was the result of both increased trabecular number and thickness ( Fig. 1 F-H) . The trabecular BV/TV was also increased in the vertebrae of Obl-Wnt16 mice (Fig. 2C) . To evaluate whether the increased trabecular bone mass in Obl-Wnt16 mice resulted in increased bone strength, L 3 vertebra was evaluated using a compression test, demonstrating that the maximal load at failure was significantly increased in Obl-Wnt16 mice compared with WT mice (Fig. 1I) . In contrast, there was only a nonsignificant tendency of increased cortical bone thickness in Obl-Wnt16 mice compared with control mice (+6.9%, P = 0.17; Fig. 1J) . Surprisingly, this demonstrates that overexpression of Wnt16 in osteoblasts increases bone mass mainly as a result of substantially increased trabecular bone mass.
The mRNA level of the anti-osteoclastogenic factor Opg was increased in the vertebral body of vertebrae L 6 , which is a bone with relatively high trabecular bone content, in Obl-Wnt16 mice compared with control mice (P < 0.05, Fig. 1K ). However, no consistent significant effect on bone formation or bone resorption was observed in Obl-Wnt16 mice compared with WT mice when Values are given as mean ± SEM *P < 0.05 vs. sham; † P < 0.05 vs. WT using Student's t test.
bone turnover was evaluated in thorough studies using (i) static histomorphometry of osteoclast number in trabecular bone of the distal femur metaphysis and vertebrae L 5 (Table S2) , (ii) dynamic histomorphometry of the trabecular bone in the distal femur metaphysis and vertebrae L 5 (Table S2) , and the cortical bone of the middiaphyseal region of femur (Table S3) , and (iii) biochemical serum bone marker analyses (Table S4 ; osteocalcin, type I collagen fragments, tartrate-resistant acid phosphatase 5b). These findings suggest that, although adult WNT16 transgenic mice have substantially increased trabecular bone mass, a new steady state of normal bone turnover has been reached in the trabecular bone.
The Bone-Sparing Effects of Estrogen and WNT16 Are Independent of Each Other When Evaluated in the Obl-Wnt16 Mouse Model. We next used the Obl-Wnt16 mouse model to test our hypothesis that the bone-sparing effect of estrogen is WNT16-dependent in female mice. This mouse model has a constant high Wnt16 expression in bone. Twelve-week-old Obl-Wnt16 and WT mice were ovx or sham-operated. Four weeks after ovx, the total body BMD, trabecular BV/TV, trabecular thickness, vertebral compression bone strength, and cortical bone thickness were reduced significantly and to a similar extent in ovx Obl-Wnt16 and ovx WT mice compared with corresponding sham-operated mice (Fig. 2 B-G) . This finding suggests that the bone-sparing effects of estrogens are not mediated via WNT16. In addition, the total body BMD, trabecular BV/ TV, trabecular thickness, and vertebral compression bone strength were higher in the ovx Obl-Wnt16 mice compared with ovx WT mice, demonstrating that the pharmacological stimulation by elevated Wnt16 level on bone mass does not require estrogen action (Fig. 2 B-F) . Notably, the total body BMD, trabecular bone volume fraction, trabecular bone thickness, and vertebral compression bone strength were similar in ovx Obl-Wnt16 mice and shamoperated WT mice, implying that WNT16 overexpression could restore these bone parameters in ovx mice (Fig. 2 B-F) . Jointly, these findings demonstrate that the bone-sparing effect of estrogen and WNT16 are independent of each other.
The Stimulatory Effect of Estrogen on Bone Does Not Require WNT16 When Evaluated in the Wnt16
−/− Mouse Model. The role of WNT16 for the bone-sparing effect of estrogen was also evaluated in
Wnt16
−/− mice. In agreement with our previous observation (3), female Wnt16 −/− mice had reduced cortical bone thickness (Fig.  3A) , whereas the tibia length and trabecular bone mass was unaffected ( Fig. 3 B-E) compared with WT mice. As adult Wnt16 −/− mice develop spontaneous tibia fractures (3), we could not, due to ethical reasons, evaluate the potential effect of ovx on the bone strength in this mouse model. Instead, we treated female gonadal intact 4-wk-old WT and Wnt16 −/− mice with a slightly supraphysiological dose of estradiol for four weeks, to further test if the stimulatory effect of estrogen on bone mass is dependent on WNT16. Estradiol treatment increased the trabecular BV/TV (Fig. 3C) as a result of increased trabecular number (Fig. 3D ) both in WT and Wnt16 −/− mice. In a similar manner, the cortical bone thickness in the middiaphyseal region of tibia was increased by estradiol treatment both in WT and Wnt16 −/− mice (Fig.  3A) . Thus, the effect of estradiol on bone does not require WNT16.
Discussion
Although it was recently established that endogenous osteoblastderived WNT16 is a crucial regulator of cortical bone mass and that the WNT16 locus associates with nonvertebral fracture susceptibility, the interaction and crosstalk between WNT16 signaling and other major regulators of bone mass is essentially unknown (3-5, 30, 34) . To determine the possible interaction between WNT16 and estrogen signaling in bone, we developed and used two genetically modified mouse models with either constantly high osteoblastic Wnt16 expression or with no Wnt16 expression. We demonstrated that the bone-sparing effects of estrogen and WNT16 are independent of each other. In addition, overexpression of WNT16 unexpectedly increased mainly trabecular bone mass.
To evaluate the interaction between estrogen action and WNT16 signaling in bone, we first developed a transgenic mouse model with osteoblast-specific Wnt16 overexpression. Endogenous WNT16 is highly expressed in cortical bone but for unknown reasons only moderately expressed in trabecular bone (3). As we used an osteoblast-specific promoter, the overexpression of Wnt16 in the OblWnt16 mouse model was bone-specific with several-fold increase of Wnt16 levels in both the trabecular and cortical bone. Indeed, Wnt16 levels in the trabecular bone of Obl-Wnt16 mice were significantly higher than in the cortical bone of WT mice. Obl-Wnt16 mice were apparently healthy but had increased total body BMD that was mainly caused by a prominent increase in trabecular bone mass both in the metaphyseal region of the long bones and in the vertebrae. These changes were further associated with improved compression strength of the vertebrae. In contrast to observations in the trabecular bone, Obl-Wnt16 mice displayed only a nonsignificant tendency for increased cortical bone mass. The unexpected finding that Wnt16 overexpression in osteoblasts results in an effect mainly in the trabecular bone is in sharp contrast to the specific reduction of cortical bone mass described in previous mouse models with either global or osteoblast specific inactivation of Wnt16 expression as well as the strong association observed between the Wnt16 locus and cortical bone thickness in human genetic studies (3, 4) . Based on these data, we propose that the high endogenous expression of WNT16 in cortical bone of WT mice results in a cortical bone mass value in the upper end of a sigmoidal dose-response curve between WNT16 expression and bone mass, with a substantial loss of cortical bone mass in the absence of WNT16 (Wnt16 −/− mice), whereas overexpression of WNT16 (Obl-Wnt16 mice) does not result in any major increase in cortical bone mass (Fig. 1L) . In contrast, the relatively modest endogenous WNT16 expression in trabecular bone of WT mice results in a trabecular bone mass value that is at the lower end of this sigmoidal WNT16 dose-response curve. Thus, no major trabecular bone loss is observed in the absence of WNT16 (3), whereas overexpression of WNT16 markedly increases trabecular bone mass, as observed in the present study (Fig. 1M) . These findings emphasize that pharmacological and physiological effects often differ, and we propose that enhancement of WNT16 signaling by pharmacological means would be useful for the treatment of trabecular bone loss. As we observed bone-site specific effects of WNT16, it is likely that osteoblast-derived WNT16, in a similar manner as observed for several other WNT proteins, acts as a shortrange local cellular signal (35) . This notion is further supported by the fact that WNT proteins are highly hydrophobic (36) .
We have previously shown that osteoblast-derived WNT16 inhibits osteoclastogenesis, both directly and indirectly via increased production of Opg (3). This is supported by the reduced Opg levels in the Wnt16 −/− mice. In the present study, the Obl-Wnt16 mice had increased Opg mRNA levels in trabecular bone, indicating that elevated Opg levels might have contributed to the increased trabecular bone mass. However, no significant alterations of bone resorption or bone formation markers were observed in the OblWnt16 mice, suggesting that although adult WNT16 transgenic mice have substantially increased trabecular bone mass, a new steady state for the bone turnover has been reached.
Postmenopausal osteoporosis is caused by a pronounced drop in estrogen levels and ovariectomy of rodents has been widely used as an animal model of this disease (37, 38) . Both estrogen and WNT16 are major regulators of bone mass (1) (2) (3) (4) (5) , and in the first phase of the present study we demonstrated that estradiol treatment increases Wnt16 expression in bone of ovx mice. We, thus, hypothesized that the bone-sparing effects of estrogens in females could be WNT16-dependent. The hypothesis was first evaluated using our Obl-Wnt16 mouse model with constant several-fold increased Wnt16 expression in both trabecular and cortical bone. However, ovariectomy reduced the trabecular and cortical bone mass similarly in Obl-Wnt16 mice and WT mice, suggesting that the bone-sparing effects of estrogen are WNT16-independent. Conversely, total body BMD and trabecular bone mass were higher in the ovx Obl-Wnt16 mice compared with ovx WT mice, demonstrating that the stimulatory effects of WNT16-overexpression on bone mass do not require estrogen action. All together, these data establish that the bone-sparing effects of estrogen and WNT16 act via independent mechanisms. Notably, the total body BMD and trabecular bone mass were similar in ovx Obl-Wnt16 mice and sham operated WT mice, implying that WNT16 overexpression restores trabecular bone mass in ovx mice.
To further evaluate the interaction between the stimulatory effects of estrogen and WNT16 on bone mass, the role of WNT16 for the bone-sparing effects of estrogen was evaluated in Wnt16 −/− mice. Estradiol treatment increased trabecular and cortical bone mass in both Wnt16 −/− and WT mice, clearly demonstrating that the stimulatory effect of estrogen on bone mass does not require WNT16 expression.
In conclusion, using two different mouse models, we here demonstrate that, although WNT16 expression is stimulated by estrogen, the bone-sparing effect of estrogen and WNT16 are independent of each other. In addition, loss of endogenous WNT16 results specifically in cortical bone loss, whereas pharmacological overexpression of WNT16, surprisingly, increases mainly trabecular bone mass. As WNT16 signaling in bone does not require normal estrogen action, we propose that WNT16-targeted therapies might be useful for treatment of postmenopausal trabecular bone loss.
Materials and Methods
Development of an Obl-Wnt16 Transgenic Mouse Line. To develop an osteoblast-specific WNT16 overexpressing mouse model (Obl-Wnt16), we generated a 4843 bp-long transgenic construct in pGL3 plasmid backbone. The transgene consists of the rat procollagen type I α 1 promoter (2.3 kb in length), simian virus 40 small-t intron as well as a full-length cDNA from mouse Wnt16 and a SV40 polyA signal (Fig. 1B) . For microinjection, the construct was linearized and cleaved from the plasmid backbone by restriction enzyme digestion using NotI and BamHI. Transgenic mouse lines were generated in the C57BL/6 genetic background by microinjecting the DNA into pronuclei of fertilized oocytes using standard techniques. Integration of the transgene was verified by PCR screening using DNA isolated from tissue biopsies obtained during ear marking of the potential founder mice, and of the offspring thereafter. The 5′-AGGAGGCACACGGAGTGAGG-3′ and 5′-CTGCTCCCATTCATCAGTTC-3′ primers were used for genotyping of the Obl-Wnt16 mice.
Establishment of an Obl-Wnt16 Transgenic Mouse Line. Obl-Wnt16 mice showed normal fertility. All experiments were carried out on mice born from crossing a male Obl-Wnt16 mouse with a female C57BL/6N mouse. WT littermates were used as control groups. The mice were fed standard phytoestrogenfree pellet diet ad libitum (R70, Lactamin AB). Ovariectomy (ovx) or sham operation were performed on 12-wk-old female mice and the mice were killed after 4 wk.
Mice with Total Inactivation of Wnt16. The generation of Wnt16 −/− mice has been described (3). Four-week-old female Wnt16 −/− and WT littermate mice were treated with vehicle or estradiol (E2, 167 ng per mouse per day) for 4 wk using slow-release pellets inserted s.c. (Innovative Research of America). All mice were housed in a standard animal facility under controlled temperature (22°C) and photoperiod (12 h of light, 12 h of dark) and the animal care was in accordance with institutional guidelines. All animal experiments had been approved by the local Ethical Committees for Animal Research at the University of Gothenburg.
Quantitative Real-Time PCR Analysis. Total RNA was prepared from humerus, middiaphyseal cortical bone of the tibia, vertebral body of vertebrae L 6 (trabecular bone) and uterus using TRIzol reagent (Life Technologies) followed by the RNeasy Mini Kit (Qiagen). The RNA was reverse transcribed into cDNA, and real-time PCR analysis was performed using predesigned real-time PCR assays for Wnt16 (Mm00446420_m1), and osteoprotegerin (Opg; Tnfrsf11b, Mm0043545_m1) on the StepOnePlus Real-Time PCR system (Applied Biosystems). The mRNA abundance of each gene was adjusted for the expression of 18S.
Dual-Energy X-Ray Absorptiometry (DXA). Analyses of total body areal BMD (aBMD) and lumbar spine (LS) BMD were performed by DXA using the Lunar PIXImus Mouse Densitometer (Wipro GE Healthcare).
High-Resolution Micro-CT (μCT). High-resolution micro-CT analyses were performed on the lumbar vertebra L 4 and tibia using an 1172 model micro-CT (Bruker micro-CT) (3). The vertebra and tibia were imaged with an X-ray tube voltage of 50 kV, a current of 201 μA, and with a 0.5-mm aluminum filter. The scanning angular rotation was 180°, and the angular increment was 0.70°. The voxel size was 4.49 mm isotropically. NRecon (version 1.6.9) was used to perform the reconstruction after the scans. In the vertebra, the trabecular bone in the vertebral body caudal of the pedicles was selected for analysis within a conforming volume of interest (cortical bone excluded) commencing at a distance of
